Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition

Ibrutinib (Imbruvica; PCI-32765) is an orally administered inhibitor of Bruton's tyrosine kinase that has transformed the treatment of B-cell malignancies. However, ibrutinib has very low oral bioavailability that contributes to significant variability in systemic exposure between patients, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisenmann, Eric D., Fu, Qiang, Muhowski, Elizabeth M., Jin, Yan, Uddin, Muhammad Erfan, Garrison, Dominique A., Weber, Robert H., Woyach, Jennifer A., Byrd, John C., Sparreboom, Alex, Baker, Sharyn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691714/
https://www.ncbi.nlm.nih.gov/pubmed/34950932
http://dx.doi.org/10.1158/2767-9764.CRC-21-0076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691714/
https://www.ncbi.nlm.nih.gov/pubmed/34950932
http://dx.doi.org/10.1158/2767-9764.CRC-21-0076

Ejemplares similares